Last Updated on January 3, 2024 by The Health Master
Drugs recall
Leading drug firms like Dr. Reddy’s Laboratories, Cipla, and Aurobindo Pharma are recalling different products in the US market for various issues, according to the US Food and Drug Administration (USFDA).
Dr. Reddy’s Laboratories
As per the enforcement report by the USFDA, the US-based unit of Dr. Reddy’s Laboratories is recalling 2,838 ampules of vitamin K deficiency treatment drug Phytonadione Injectable Emulsion.
According to the USFDA, Dr. Reddy’s Laboratories is recalling the affected lot due to “failed stability specifications”.
“Out-of-specification results were reported at 12-month stability testing for aluminum content,” it stated.
Dr. Reddy’s initiated the Class III voluntary recall on September 14 this year.
As per USFDA, a Class III recall is initiated in a “situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences”.
Cipla
The USFDA further said the US-based arm of domestic drug major Cipla is recalling 9,041 cartons of Arformoterol Tartrate Inhalation Solution, which is used to help control the symptoms of chronic obstructive pulmonary disease (COPD).
The company is recalling the affected lots due to “lack of assurance of sterility: environmental monitoring failure”.
The affected lot has been produced by Cipla at its Madhya Pradesh-based plant.
Cipla commenced a Class II recall in the US on September 30, 2022. As per USFDA, a Class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
Aurobindo Pharma
The USFDA said AuroMedics Pharma LLC, a unit of Hyderabad-based Aurobindo Pharma, is recalling 88,080 vials of tranexamic acid injection, which is used to control or prevent excessive or heavy bleeding during various conditions like dental procedures in patients.
The East Windsor-based drug firm is recalling the affected lot due to the “presence of particulate matter: a piece of metal found in a vial,” the USFDA stated.
AuroMedics commenced the Class III recall in the US on September 26.
According to industry estimates, the US generic drug market was estimated to be worth around USD 115.2 billion in 2019. It is the largest market for pharmaceutical products.
Drug recall: Sodium Bicarbonate Injection recalled due to this reason
Drug recall: Acyclovir Sodium Injection recalled due to this reason
Drug recall: Zydus, Lupin recall products due to this issue
Drug recall: Glenmark, Strides Pharma, Cipla recalled these drugs
Drug recall: Glenmark, Sun, Dr Reddy’s recalled these Drugs
Drug recall: Atorvastatin 40 mg tablets recalled due to this reason
Drug recall: Sodium Bicarbonate Injection recalled due to this reason
USFDA clears Intelligent Ultrasound’s AI for real-time guidance
CDSCO Panel gives conditional nod for Nimesulide Granules
USFDA issues form 483 with 17 observations to Lupin
Govt notifies rules to exempt certain medical devices under Class A
PCI to implement Pharmacy Practice Regulations, 2015
Drug alert: 59 out of 1456 samples declared as NSQ in September 2022
Govt notifies rules to ease New Drugs and Clinical Trials norms
Govt brings these eight substances under NDPS Act
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
